Gallium-68 DOTANOC scan in a patient with suspected cardiac sarcoidosis

Passah, Averilicia; Kaushik, Prateek; Patel, Chetan; Parakh, Neeraj

doi:10.1007/s12350-017-1178-3

Cited by 9 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded SSTR PET may be more specific for acute inflammation and bear a potential role in treatment response. Other earlier or smaller studies demonstrated similar or improved performance of SSTR-PET tracers compared with [ 18 F]FDG [ 26 , 27 , 28 , 29 , 30 ]. A case of neurosarcoidosis imaged with [ 68 Ga]Ga-DOTATATE was reported by Unterrainer et al [ 31 ].…”

Section: Discussionmentioning

confidence: 87%

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

et al. 2022

View full text Add to dashboard Cite

Somatostatin receptor (SSTR) agonist tracers used in nuclear medicine scans are classically used for neuroendocrine tumor diagnosis and staging. SSTR are however, expressed more widely in a variety of cells as seen in the distribution of physiological tracer uptake during whole body scans. This provides opportunities for using these tracers for applications other than NETs and meningiomas. In this qualitative systematic review, novel diagnostics in SSTR-PET imaging are reviewed. A total of 70 studies comprised of 543 patients were qualitatively reviewed. Sarcoidosis, atherosclerosis and phosphaturic mesenchymal tumors represent the most studied applications currently with promising results. Other applications remain in progress where there are many case reports but a relative dearth of cohort studies. [18F]FDG PET provides the main comparative method in many cases but represents a well-established general PET technique that may be difficult to replace, without prospective clinical studies.

show abstract

Section: Discussionmentioning

confidence: 87%

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In another case, Biventricular SPECT with technetium-99 m was used as a clinically useful tool for the noninvasive assessment of both ventricles in a patient with sarcoidosis (55). Using two imaging techniques like, Tc 99 m MIBI and Ga-68DOTANOC PET-CT is also fruitful in confirming suspected CS (56). Another significant support in this labyrinth of CS is provided by Thallium Myocardial Perfusion Imaging, which was very helpful in monitoring response to treatment, as in this case, it could not be done by MR because of the ICD (57).…”

Section: Radionuclide Scanmentioning

confidence: 99%

Cardiac sarcoidosis: a comprehensive review of risk factors, pathogenesis, diagnosis, clinical manifestations, and treatment strategies

Shah,

Zehra,

Shahrukh

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Cardiac Sarcoidosis (CS) is a deadly consequence of systemic sarcoidosis that inflames all three layers of the heart, especially the myocardium—clinical signs of CS range from asymptomatic disease to abrupt cardiac death. CS generally remains undiagnosed secondary to a lack of definitive diagnostic criteria, a high percentage of false negative results on endomyocardial biopsy, and ill-defining clinical manifestations of the disease. Consequently, there is a lack of evidence-based recommendations for CS, and the present diagnostic and therapeutic management depend on expert opinion. The aetiology, risk factors, clinical symptoms, diagnosis, and therapy of CS will be covered in this review. A particular emphasis will be placed on enhanced cardiovascular imaging and early identification of CS. We review the emerging evidence regarding the use of Electrocardiograms (ECGs), Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET) imaging of the heart to identify and quantify the extent of myocardial inflammation, as well as to guide the use of immunotherapy and other treatment regimens, such as ablation therapy, device therapy, and heart transplantation, to improve patient outcomes.

show abstract